ALERT: 1 Pharma Stock for Value Investors With a Significant Margin of Safety

HLS Therapeutics Inc. (TSX:HLS) makes competitively sound and typically modest pricing adjustments to maintain product viability and competitiveness.

pharma, vaccine, coronavirus, COVID

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

HLS Therapeutics (TSX:HLS) is a North American-based specialty pharmaceutical company focused on commercializing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) market. HLS holds a diversified portfolio of royalty interests on global sales of four different pharmaceutical products, which, in effect, provides HLS with income based on worldwide sales of such products.

HLS pursues additional product and pipeline opportunities in the CNS therapeutic markets through targeted business development efforts. HLS’s experienced management team has a long and proven track record of successfully sourcing, developing, and commercializing drugs in a variety of therapeutic areas at every stage of the lifecycle throughout North America and internationally. In the financial years ended 2019 and 2020, HLS generated revenues of $54.2 million and $56.1 million, respectively.

Product acquisition expertise

Members of HLS’s executive management team and the HLS board have on average more than 20 years of pharmaceutical product acquisition and operational experience. As a result, the HLS management team has a broad network within the industry and a proven track record of success. HLS’s team is also experienced in various aspects of governance, corporate financing, pharmaceutical operations. In addition, members of management maintain a significant ownership interest in HLS in order to align interests with shareholders.

Superior business model

Similar to Trillium, HLS also has the flexibility to consider a broad range of acquisition targets from a variety of therapeutic areas in addition to the CNS space. Because HLS has operations in both Canada and the United States, it has the ability to acquire and commercialize products in either or both countries. Such flexibility is advantageous to certain vendors or licensors.

Predictable cost structure

The company’s management has considerable experience managing commercial-stage pharmaceutical operations in North American markets. HLS’s management has established a predictable cost structure by relying on a small but experienced employee base and outsourcing to leading outsource service providers certain of the operational functions associated with HLS’s business, including warehousing, distribution, customer service, and regulatory affairs.

This predictability, scalability, flexibility and efficiency gained by contracting with established, experienced service organizations assists HLS in improving HLS’s margins, achieving profitability and facilitating growth. Further, the HLS model is not dependent on price increases. HLS makes competitively sound and typically modest pricing adjustments to maintain product viability and competitiveness.

Partnership with leading service providers

HLS has a network of leading external advisors. While retaining strategic direction and direct oversight, the company enters relationships with select leading providers of pharmaceutical contract services for many of the operational functions associated with HLS’s business. These outsourcing relationships minimize the need for significant overhead and provide HLS with scalability, and flexibility to adapt to market conditions in a cost-effective manner.

Robust business strategy

Overall, HLS’s business strategy is to acquire a diversified portfolio of branded pharmaceutical products for commercialization in North American markets. HLS’s current strategic focus is on the acquisition and distribution of pharmaceuticals that address unmet medical needs in specialty CNS disorders, such as schizophrenia. HLS is well positioned to focus on these therapeutic areas to add significant shareholder value.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

growing plant shoots on stacked coins
Dividend Stocks

2 Oversold TSX Dividend Stocks to Buy Now and Own for 25 Years

These top TSX dividend stocks look oversold and now offer attractive yields for TFSA and RRSP investors.

Read more »

money cash dividends
Investing

Passive-Income Power: How to Make $105/Week TAX FREE in a Bear Market

Investors may want to pursue a passive-income strategy in this bear market by snagging dividend stocks like Freehold Royalties Ltd.…

Read more »

Money growing in soil , Business success concept.
Energy Stocks

3 Growth Stocks up +30% in 2022

These three growth stocks are up over 30% in 2022 alone but have come down in the last few weeks…

Read more »

Oil pumps against sunset
Energy Stocks

2 Energy Stocks That Jumped Over 60% This Year

Consider investing in these two energy stocks amid the recent pullback after putting up stellar gains earlier this year.

Read more »

Profit dial turned up to maximum
Dividend Stocks

RRSP Investors: 2 Undervalued TSX Stocks to Buy Now for Total Returns

Top TSX dividend stocks are now on sale for RRSP investors seeking attractive total returns.

Read more »

TFSA and coins
Dividend Stocks

2 Beaten-Down Stocks to Buy for Your TFSA

Two beaten-down, but high-yield TSX stocks are profitable options for TFSA investors.

Read more »

Volatile market, stock volatility
Stocks for Beginners

3 Top TSX Stocks to Buy in Volatile Markets

Sitting on cash? Consider these three TSX stocks for the long term.

Read more »

Hand writing Time for Action concept with red marker on transparent wipe board.
Dividend Stocks

Inflation Soars to 7.7%: 1 Dividend Stock to Buy Now

Enbridge (TSX:ENB)(NYSE:ENB) stock looks like a magnificent dividend stock to help Canadians deal with inflation at 7.7%.

Read more »